Data updated: Jun 28, 2026
Overactive Bladder Clinical Trial Landscape
Overactive Bladder is being studied across 315 clinical trials registered since 2008, with 40 programs currently active. The competitive pipeline includes 8 active Phase 3 trials, 12 active Phase 2 trials, and 2 active Phase 1 trials.
Top industry sponsors include Levee Medical, Inc., Cook MyoSite, TBF Genie Tissulaire.
Trial activity
40 active / 315 total since 2008
Active by phase 8 Ph3 / 89 12 Ph2 / 71 2 Ph1 / 47 18 Ph4 / 108
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Levee Medical, Inc. 2 0 0
Cook MyoSite 1 5 1
TBF Genie Tissulaire 1 1 0
Vensica Therapeutics Ltd. 1 0 0
Eli Lilly 1 0 0
Trigone Pharma Ltd. 1 0 0
Astellas 0 18 2
AbbVie 0 16 1
Pfizer 0 11 0
Bayer 0 7 0
Urovant Sciences GmbH 0 6 0
Jeil Pharmaceutical Co., Ltd. 0 5 0
Taiho Pharmaceutical Co., Ltd. 0 4 0
GTx 0 2 2
Merck 0 3 1
How the field has grown
New-trial starts peaked in 2016 (25 registered); 2025 saw 12. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (34 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 25
2017 14
2018 19
2019 14
2020 18
2021 11
2022 13
2023 9
2024 12
2025 12
2026 11
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (7) 123
2017 (2) 185
2018 (5) 132
2019 (5) 137
2020 (2) 180
2021 (2) 63
2022 (3) 66
2023 (2) 107
2024 (2) 138
2025 (3) 266
2026 (1) 60
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT05878951 RECRUITING
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Northwestern University n=66
NCT07202884 RECRUITING
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company n=1,000
NCT03104517 ACTIVE NOT RECRUITING
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
Cook MyoSite n=96
NCT07429734 NOT YET RECRUITING
Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women
Mansoura University n=60
NCT03952299 RECRUITING
Oxybutynin for Post-surgical Bladder Pain and Urgency
University of California, Davis n=100
NCT06551246 RECRUITING
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
University of Aarhus n=236
NCT06678984 NOT YET RECRUITING
Treated Umbilical Vein Allograft (UVT) Versus Autologous Fascial Pubovaginal Sling in the Treatment of Female Stress Urinary Incontinence
TBF Genie Tissulaire n=96
NCT07366762 COMPLETED
Comparison Between Two Techniques in Treatment of Female Stress Urinary Incontinence
Kafrelsheikh University n=40
NCT04171531 COMPLETED
Sling vs Botox for Mixed Incontinence
NICHD Pelvic Floor Disorders Network n=150
NCT05702827 COMPLETED
Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery
TriHealth Inc. n=148
NCT04641975 TERMINATED
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
Astellas Pharma Global Development, Inc. n=26
NCT01972841 COMPLETED
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Astellas Pharma Europe B.V. n=3,527
NCT02045862 COMPLETED
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
Astellas Pharma Europe B.V. n=1,829
NCT03149809 COMPLETED
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
VA Office of Research and Development n=77
NCT03997318 WITHDRAWN
Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair(JPN1)
Cook MyoSite
NCT04103450 COMPLETED
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Urovant Sciences GmbH n=276
NCT03902080 COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Urovant Sciences GmbH n=1,105
NCT05282069 COMPLETED
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
Dong-A ST Co., Ltd. n=607
NCT04048356 COMPLETED
Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures
University of New Mexico n=137
NCT01893138 COMPLETED
Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
Cook MyoSite n=311
NCT02097121 TERMINATED
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
Allergan n=56
NCT02660359 TERMINATED
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
Ipsen n=258
NCT02660138 TERMINATED
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
Ipsen n=227
NCT04412876 WITHDRAWN
Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study
Far Eastern Memorial Hospital
NCT02352103 COMPLETED
Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
Henry Ford Health System n=120
NCT04917315 COMPLETED
To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder
Jeil Pharmaceutical Co., Ltd. n=210
NCT03524339 COMPLETED
Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery
University Hospitals Cleveland Medical Center n=132
NCT03583372 COMPLETED
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
Urovant Sciences GmbH n=506
NCT03492281 COMPLETED
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
Urovant Sciences GmbH n=1,530
NCT04534491 COMPLETED
Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.
Bayer n=855
NCT01959347 COMPLETED
Combined Treatment for Mixed Incontinence
NICHD Pelvic Floor Disorders Network n=480
NCT01852058 COMPLETED
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Allergan n=95
NCT01786967 COMPLETED
Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
University of North Carolina, Chapel Hill n=61
NCT01852045 COMPLETED
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
Allergan n=114
NCT02529865 COMPLETED
Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence
Nagoya University n=45
NCT02614482 COMPLETED
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
Stéphane Bolduc n=26
NCT02327936 COMPLETED
Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
Stéphane Bolduc n=62
NCT03575702 COMPLETED
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
R-Pharm n=300
NCT00876447 COMPLETED
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
Allergan n=397
NCT00915525 COMPLETED
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Allergan n=829
NCT01600716 COMPLETED
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Allergan n=144
NCT01767519 COMPLETED
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Allergan n=356
NCT01220726 COMPLETED
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
Weill Medical College of Cornell University n=30
NCT02263534 COMPLETED
Comparing Minisling to Tension Free Vaginal Tape in Mangement of Stress Urinary Incontinence
Ain Shams University n=48
NCT02468830 COMPLETED
Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
CHU de Quebec-Universite Laval n=58
NCT01382602 COMPLETED
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
Cook MyoSite n=150
NCT01502956 COMPLETED
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
NICHD Pelvic Floor Disorders Network n=386
NCT01166438 COMPLETED
Anticholinergic vs. Botox Comparison Study
NICHD Pelvic Floor Disorders Network n=249
NCT02476175 COMPLETED
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
CHU de Quebec-Universite Laval n=35
NCT02805452 TERMINATED
Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer
Center Eugene Marquis n=4
NCT01520948 COMPLETED
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Atlanta VA Medical Center n=53
NCT02129816 TERMINATED
Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder
University of Zurich n=9
NCT03296748 COMPLETED
Correction of Asymptomatic 2nd Degree Cystocele in Patient With Stress Incontinence
Kasr El Aini Hospital n=123
NCT02334878 COMPLETED
Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence
Ain Shams Maternity Hospital n=50
NCT01175382 COMPLETED
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
University of Alabama at Birmingham n=204
NCT03059134 COMPLETED
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
Buddhist Tzu Chi General Hospital n=168
NCT02485067 COMPLETED
Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB
SK Chemicals Co., Ltd. n=384
NCT00685217 TERMINATED
Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT)
University of Calgary n=74
NCT00685113 COMPLETED
A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder
Duramed Research n=1,104
NCT02143570 COMPLETED
Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
Universidad de Valparaiso n=80
NCT00527696 TERMINATED
Trial Comparing TVT SECUR System and Trans Vaginal Obturator Tape for Surgical Management of Stress Urinary Incontinence
University of Manitoba n=106
NCT00909181 COMPLETED
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
Antares Pharma Inc. n=626
NCT01384084 COMPLETED
Pelvic Organ Prolapse Repair Plus Mini-Sling Versus Pelvic Organ Prolapse Repair Alone
University Of Perugia n=50
NCT01067261 COMPLETED
Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Preservation and Restoration of Urinary Continence and Erectile Function and in the Treatment of Erectile Dysfunction and Urinary Incontinence in Conjunction With Nerve Sparing Radical Prostatectomy
Copenhagen University Hospital at Herlev n=68
NCT01366066 TERMINATED
Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence
Copenhagen University Hospital at Herlev n=4
NCT01148290 COMPLETED
Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence
University Magna Graecia n=40
NCT00910845 COMPLETED
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Allergan n=557
NCT00910520 COMPLETED
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Allergan n=548
NCT01464372 TERMINATED
Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder
EMKinetics, Inc n=130
NCT01628991 COMPLETED
Behavioral Intervention Program and Vaginal Cones on SUI
Mashhad University of Medical Sciences n=60
NCT00801203 COMPLETED
A Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence
Pneumoflex Systems, LLC n=180
NCT00695058 WITHDRAWN
Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence
Copenhagen University Hospital at Herlev
NCT01512004 COMPLETED
Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder
Lee's Pharmaceutical Limited n=324
NCT00611026 COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
Pfizer n=2,417
NCT00658684 COMPLETED
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
Pfizer n=153
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only